Items Tagged ‘cemiplimab’

February 2, 2018

PD-1 Antibody Cemiplimab Appears Promising for Treatment of Squamous Cell Carcinoma of the Skin


Cemiplimab an investigational human antibody targeting PD-1 (programmed cell death protein 1), is yet another “checkpoint inhibitor” that was evaluated in 82 patients with advanced cutaneous squamous cell carcinoma (CSCC).  Early trial results suggest that cemiplimab may represent a viable treatment option for individuals diagnosed with CSCC. About Cutaneous Squamous Cell Carcinoma (CSCC) CSCC is […]

View full entry

Tags: cemiplimab, immunotherapy, News, PD-1, Skin Cancer